Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment

Türker, Sema; Çılbır, Ebru; Karaçin, Cengiz; Altınbaş, Mustafa

doi:10.4103/jcrt.jcrt_343_17

Cited by 4 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Xerosis, pruritus, fissures, nail/subungual abnormalities, mucosal inflammation or aphthae are also described. 1,3,6…”

Section: Discussionmentioning

confidence: 99%

“…1,6 Surveying, there are sporadically published hair cycle disorders; hair loss either as scarring/non-scarring alopecia or as brittle, fine vellus hair. 1,3,6 The other pattern of hypertrichosis depicting as facial area, cheeks and eyebrows hypertrichosis, including sometimes body trunk and extremities, is also in the literature presented. 1,3,6,7 Ears when presented with hair growth mimicking hairy pinnae have also been cited in two male cases due to EGFR inhibitor therapies.…”

Section: Discussionmentioning

confidence: 99%

“…5 In addition, there are several reported cases of simultaneous hypertrichosis, trichomegaly and androgenetic alopecia in cetuximab-treated patients revealing a confirmed complex EGFR role in the hair cycle regulation phase. 6 It is noticeable, all so far conducted basic research, to determine EGF key role in hair growth cycle. Specifically, Mak and Chan have cited EGF as a fundamental factor in hair morphogenesis, entitled as 'first anagen phase', beyond its active regulator participation in hair development physiology later, based on studies of mice experimental hair cycles.…”

Section: Discussionmentioning

confidence: 99%

“…3 EGFR is not absent from adnexal epithelium(sebaceous/eccrine glands) and hair follicles; as basic regulators in follicular cell differentiation, proliferation and growth. 3,5,6 Thus, the extensive EGFR expression in epidermal tissue, may explain the exacerbating skin's adverse reactions caused by anti-EGFR-targeted medication antibodies. Literature surveillance shows the most common clinical manifestations engaged in mucous and cutaneous membranes.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Pinnae and facial hypertrichosis induced by cetuximab

Alexandris

Alevizopoulos

Palamaris

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform papules and skin disorders. Hypertrichosis cited in face pinnae and eyelash trichomegaly are seldom described. Case report A 72-year-old female cancer patient presented deteriorating facial-pinnae hypertrichosis and eyelash prolongation post cetuximab infusion. Management and outcome Consecutive cetuximab administration led to exaggerating hairy skin side effects, fully alleviated when the drug was discontinued. Discussion To the best of our knowledge, this is the first reported case of an anti-EGFR-associated diffuse pinnae hypertrichosis presentation in a female patient in literature. This distinct entity can be easily diagnosed and manipulated with early drug withdrawal. An extensive review of relevant basic molecular research is provided to increase physicians’ awareness.

show abstract

“…1,2 Xerosis, pruritus, fissures, nail/subungual abnormalities, mucosal inflammation or aphthae are also described. 1,3,6…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pinnae and facial hypertrichosis induced by cetuximab

Alexandris

Alevizopoulos

Palamaris

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…EGFR is not only expressed on tumor cells, but also on skin cells and is important for normal skin development and function. For this reason, cetuximab has unique cutaneous side effects including acneiform eruption, pruritus, xerosis, desquamation, paronychia, and changes in hair growth [5-7]. These skin reactions are seen in about 80% of patients treated with cetuximab and lead to dose reduction or termination of cetuximab in about 15–25% of patients [3, 8, 9].…”

Section: Introductionmentioning

confidence: 99%

Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption

et al. 2020

View full text Add to dashboard Cite

Background: Acneiform eruption is the most common cutaneous adverse event associated with cetuximab. As it can affect quality of life and adversely affect chemotherapy schedule, additional medical care is required. Objectives: To investigate the adherence to and the duration of antibiotic administration to treat cetuximab-induced acneiform eruption. Methods: Medical data of patients who were referred to the Department of Dermatology were reviewed from January 2013 to June 2018. Dermatologists assessed the severity of acneiform eruption and prescribed tetracycline-class antibiotics according to the severity every 2 or 4 weeks. We investigated the duration and amount of oral antibiotic administration and analyzed the factors that may affect the control of acneiform eruption statistically. Results: A total of 207 of 267 patients referred to the Department of Dermatology showed acneiform eruption; 124 patients were treated with minocycline, 34 patients with doxycycline, 27 patients with both, and 22 patients with topical agents. The mean duration of oral antibiotic medication was 82.7 days. A statistical analysis of the factors that prolonged the use of antibiotics for more than 90 days showed that male and younger age were risk factors. Shorter time interval from starting cetuximab to starting antibiotics was associated with longer duration of antibiotic use, statistically. Conclusions: Cetuximab-induced acneiform eruption can be well controlled with tetracycline-class antibiotics in about 3 months. It can last longer in male and younger patients. The sooner and the more severe it appears, the longer it can last.

show abstract

Cetuximab

2020

Reactions Weekly

View full text Add to dashboard Cite

Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment

Cited by 4 publications

References 7 publications

Pinnae and facial hypertrichosis induced by cetuximab

Pinnae and facial hypertrichosis induced by cetuximab

Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption

Cetuximab

Contact Info

Product

Resources

About